← Back to catalogue

Interleukin-2 Receptor Chemiluminescence Immunoassay Kit

EUDAMED

Class IVD General (EU MDR)

Ref S2034E-100Ref S2034E-150Ref S2034E-50Ref S2034E-200Ref S2034E-75

by Sansure Biotech Inc.

Identity

Device Name
Interleukin-2 Receptor Chemiluminescence Immunoassay Kit EUDAMED
Model / Reference
S2034E-100 EUDAMED
S2034E-150 EUDAMED
S2034E-50 EUDAMED
S2034E-200 EUDAMED
S2034E-75 EUDAMED

Identifiers

Primary DI / UDI-DI
06955792738898 EUDAMED
06955792738904 EUDAMED
06955792738874 EUDAMED
06955792738911 EUDAMED
06955792738881 EUDAMED
Basic UDI-DI
B-06955792738898 EUDAMED
B-06955792738904 EUDAMED
B-06955792738874 EUDAMED
B-06955792738911 EUDAMED
B-06955792738881 EUDAMED
EMDN Code
W01030607 INTERLEUKINS RECEPTORS (IL-2R,IL6R ...) EUDAMED

Classification

Device Class
Class IVD General EUDAMED
Market of Registration
France EUDAMED

Clinical & Handling

Sterile

No

EUDAMED

Human Tissues

No

EUDAMED

Animal Tissues

Yes

EUDAMED

Microbial Substances

Yes

EUDAMED

Reagent

Yes

EUDAMED

Self Testing

No

EUDAMED

Near-Patient Testing

No

EUDAMED

Professional Testing

Yes

EUDAMED

Companion Diagnostics

No

EUDAMED

Surgical Instrument

No

EUDAMED

Interleukin-2 Receptor Chemiluminescence Immunoassay Kit by Sansure Biotech Inc. — Class IVD General — IVDD — listed in EUDAMED — regulatory data on deviCERTS

Authorization Coverage (European Union — 27 member states)

Regulatory Authorizations

European Union Active

CE/IVDD

Is this your device? Claim it to add documentation and request validation.

Manufacturer

EUDAMED SRN
CN-MF-000011392
Authorised Representative
Obelis s.a. BE-AR-000000106

Sources (5)

  • EUDAMED bcebfc42-d489-4bac-aea2-c15325162be3 61 fields · synced Aug 3, 2026
  • EUDAMED 087defc9-0e2e-4a82-af78-17d9b3c8e2ae 61 fields · synced May 17, 2026
  • EUDAMED 52fdf470-28eb-4aef-b3a2-a5c5fb4c0949 61 fields · synced May 17, 2026
  • EUDAMED cd1487b3-55e4-4e00-9723-ec5bc7abc90c 61 fields · synced May 17, 2026
  • EUDAMED ca7861fd-2bbf-4a37-b8df-4e457ba4b68c 61 fields · synced May 18, 2026